Clinical outcomes of transcatheter selective superior mesenteric artery urokinase infusion therapy vs transjugular intrahepatic portosystemic shunt in patients with cirrhosis and acute portal vein thrombosis

Figure 1 The process of patient inclusion and exclusion. PVT: Portal vein thrombosis; TIPS: Transjugular intrahepatic portosystemic shunt; SMA: Superior mesenteric artery.

Figure 2 Contrast images of angio-computed tomography before and after transcatheter selective superior mesenteric artery urokinase infusion therapy in a patient. A: A patient with MPV complete blocking and cavernous transformation (grade III) before urokinase infusion; B: 6 mo after urokinase infusion, MPV achieved sustained recanalization, but there was still cavernous transformation.

Figure 3 Rebleeding and hepatic encephalopathy in the two groups. A: Cumulative rate free of the first episode of rebleeding in the superior mesenteric artery (SMA) group and transjugular intrahepatic portosystemic shunt (TIPS) group (P = 0.320, log-rank test); B: Cumulative rate free of the first episode of hepatic encephalopathy in the SMA group and TIPS group (P = 0.022, log-rank test).